RhumbLine Advisers
GMAB icon

RhumbLine Advisers’s Genmab GMAB Stock Holding History

RhumbLine Advisers’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
39,985
+423
+1% +$11.2K ﹤0.01% 2259
2026
Q1 		$1.06M Buy
39,562
+2,500
+7% +$74.9K ﹤0.01% 2164
2025
Q4 		$1.14M Buy
37,062
+21,048
+131% +$656K ﹤0.01% 2157
2025
Q3 		$491K Sell
16,014
-1,193
-7% -$29.1K ﹤0.01% 2713
2025
Q2 		$355K Buy
17,207
+251
+1% +$5.15K ﹤0.01% 2891
2025
Q1 		$332K Buy
16,956
+532
+3% +$11.2K ﹤0.01% 2827
2024
Q4 		$343K Sell
16,424
-2,430
-13% -$53.4K ﹤0.01% 2907
2024
Q3 		$460K Buy
18,854
+160
+0.9% +$4.28K ﹤0.01% 2749
2024
Q2 		$470K Buy
18,694
+1,236
+7% +$35K ﹤0.01% 2727
2024
Q1 		$522K Buy
17,458
+1,602
+10% +$47.1K ﹤0.01% 2641
2023
Q4 		$505K Sell
15,856
-385
-2% -$12.1K ﹤0.01% 2655
2023
Q3 		$573K Buy
16,241
+311
+2% +$11.9K ﹤0.01% 2534
2023
Q2 		$605K Buy
+15,930
New +$635K ﹤0.01% 2571
2021
Q1 		– Sell
-5,677
Closed -$231K – 3001
2020
Q4 		$231K Buy
+5,677
New +$212K ﹤0.01% 2776

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RhumbLine Advisers's GMAB Position: Q2 2026 in Review

RhumbLine Advisers increased its Genmab (GMAB) stake by 1.1% in Q2 2026, buying an estimated $11.2K and bringing the position to 39,985 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

RhumbLine Advisers first reported a position in GMAB in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.14M in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • RhumbLine Advisers held 39,985 shares of Genmab worth $1.1M as of Q2 2026.
  • RhumbLine Advisers bought 423 Genmab shares in Q2 2026, an estimated $11.2K.
  • Genmab made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2259 holding.
  • RhumbLine Advisers first reported a position in Genmab in Q4 2020 and has held it in 14 quarters since.
  • RhumbLine Advisers's Genmab position peaked at $1.14M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.